Interfering with capsid formation: A practicable antiviral strategy against hepatitis B virus?
Authors:
- Hartmut JaeschkeHJHartmut Jaeschke
- Kevin MullenKMKevin Mullen
- Darius MoradpourDMDarius Moradpour
- 1 March 2004
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 39 (3) , 838-840
Abstract
Chronic hepatitis B virus (HBV) infection is a major cause of liver disease. Only interferon-alpha and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy. However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors. Potent new antiviral compounds suitable for monotherapy or combination therapy are highly desired. We describe nonnucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity. These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.Keywords
This publication has 19 references indexed in Scilit:
- Nuclear import of hepatitis B virus capsids and release of the viral genomeProceedings of the National Academy of Sciences, 2003
- Central Role of a Serine Phosphorylation Site within Duck Hepatitis B Virus Core Protein for Capsid Trafficking and Genome ReleaseJournal of Biological Chemistry, 2003
- Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of NucleocapsidsScience, 2003
- Hepatitis B Virus BiologyMicrobiology and Molecular Biology Reviews, 2000
- Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesisHepatology, 1999
- Phosphorylation-dependent Binding of Hepatitis B Virus Core Particles to the Nuclear Pore ComplexJournal of Cell Biology, 1999
- Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfectionThe EMBO Journal, 1998
- Long-term follow-up of patients with chronic hepatitis B treated with interferon alfaGastroenterology, 1997
- Use of Dominant Negative Mutants of the Hepadnaviral Core Protein As Antiviral AgentsHepatology, 1996
- Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.Proceedings of the National Academy of Sciences, 1987